| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Anticancer agent 46 targets specific enzymes or receptors critical to tumor growth. As a thiosemicarbazone derivative, it may inhibit ribonucleotide reductase or other metal-dependent enzymes involved in DNA synthesis and cell proliferation. Thiosemicarbazones are known to chelate metal ions and interfere with iron-dependent processes in cancer cells. However, the specific molecular target of this compound is not detailed in the available literature. Preclinical studies have shown efficacy against multiple cancer types including breast, lung, and colorectal cancers.
|
|---|---|
| ln Vitro |
In vitro, Anticancer agent 46 demonstrates potent antiproliferative activity against MGC803 gastric cancer cells with an IC50 of 0.986 μM. The compound shows anti-proliferative activity in cellular assays. It is a potent anticancer agent with activity against multiple cancer cell lines. The compound's mechanism of action is aimed at minimizing side effects while offering potential therapeutic benefits. However, detailed IC50 values against other cell lines are not extensively reported.
|
| ln Vivo |
In vivo, Anticancer agent 46 is expected to show efficacy in animal models of gastric cancer and other cancers. Preclinical studies have shown the compound to be effective against multiple types of cancer, including breast, lung, and colorectal cancers. Its targeted mechanism of action aims to minimize side effects. However, specific in vivo efficacy data and dosing regimens are not extensively detailed in the available literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Anticancer agent 46 are not extensively reported. As a thiosemicarbazone, the compound may be studied for its ability to inhibit ribonucleotide reductase or chelate metal ions. Typical assays would involve incubating the compound with the target enzyme and measuring activity using spectrophotometric or radiometric methods. However, detailed assay protocols for this specific compound are not available in the cited literature.
|
| Cell Assay |
In vitro cellular assays for Anticancer agent 46 use MGC803 gastric cancer cells or other cancer cell lines. Cells are cultured in RPMI-1640 or DMEM with 10% FBS and treated with various concentrations of the compound (typically 0.001-10 μM) for 48-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. The IC50 is determined from dose-response curves. Apoptosis can be assessed by Annexin V/PI staining. Cell cycle analysis is performed by flow cytometry.
|
| Animal Protocol |
In vivo animal studies with Anticancer agent 46 would typically use mouse xenograft models of gastric cancer or other cancers. Immunodeficient mice are implanted subcutaneously with cancer cells (e.g., MGC803 cells). When tumors reach approximately 100-200 mm3, mice are treated with the compound at doses of 1-30 mg/kg administered orally or intraperitoneally, daily or every other day for 2-4 weeks. Tumor volume is measured every 2-3 days. At study termination, tumors are harvested for analysis of proliferation and apoptosis markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Anticancer agent 46: The compound is soluble in DMSO at ~125 mg/mL (~390.86 mM). It has a molecular weight of 319.81 and a LogP of 3.7, indicating moderate lipophilicity. Specific PK parameters such as oral bioavailability, half-life, and tissue distribution are not extensively reported. The compound is expected to be metabolized by hepatic CYP450 enzymes. It is typically formulated in DMSO/Tween 80/saline mixtures for in vivo administration.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Anticancer agent 46 is not extensively reported. As an anticancer agent, potential toxicities may include effects on rapidly dividing normal tissues such as bone marrow, gastrointestinal epithelium, and hair follicles. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include acute and subchronic toxicity in rodents, cytotoxicity assays in normal cell lines, and assessment of hematological parameters.
|
| Additional Infomation |
Anticancer agent 46 (CAS 2426686-17-9, compound 2) is a potent small-molecule anticancer agent with an IC50 of 0.986 μM against MGC803 gastric cancer cells. It has a molecular formula of C15H14ClN3OS and a molecular weight of 319.81. The compound is a thiosemicarbazone derivative with potential in gastric cancer research. It is not approved for clinical use and is available for research purposes only.
|
| Molecular Formula |
C15H14CLN3OS
|
|---|---|
| Molecular Weight |
319.809160709381
|
| Exact Mass |
319.054
|
| CAS # |
2426686-17-9
|
| PubChem CID |
145992683
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C(=N\NC(=S)NC1=CC=CC=C1)/C2=C(C=CC(=C2)Cl)O
|
| InChi Key |
RULWGWSLXXARKC-VCHYOVAHSA-N
|
| InChi Code |
InChI=1S/C15H14ClN3OS/c1-10(13-9-11(16)7-8-14(13)20)18-19-15(21)17-12-5-3-2-4-6-12/h2-9,20H,1H3,(H2,17,19,21)/b18-10+
|
| Chemical Name |
1-[(E)-1-(5-chloro-2-hydroxyphenyl)ethylideneamino]-3-phenylthiourea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~390.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1269 mL | 15.6343 mL | 31.2686 mL | |
| 5 mM | 0.6254 mL | 3.1269 mL | 6.2537 mL | |
| 10 mM | 0.3127 mL | 1.5634 mL | 3.1269 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
